Company Overview

EHAVE, Inc. is a micro-cap technology company focused on digital health, specifically data analytics and software platforms supporting mental health, addiction treatment, and psychedelic-assisted therapy workflows. The company operates at the intersection of healthcare IT and behavioral health services, developing tools intended to improve clinical decision-making, treatment monitoring, and outcomes reporting for providers and researchers.

The company’s strategy centers on building data-driven platforms for regulated healthcare environments rather than direct patient care. EHAVE has evolved through a series of platform development efforts and small acquisitions aimed at assembling analytics capabilities for emerging treatment modalities. Public disclosures indicate the company has undergone multiple strategic pivots since inception, reflecting its early-stage nature and changing market focus. Certain historical details and revenue scale remain data inconclusive based on available public sources.

Business Operations

EHAVE generates or intends to generate revenue through software licensing, data analytics services, and platform subscriptions offered to healthcare providers, clinics, and research organizations. Its operations are organized around digital platforms designed to collect, analyze, and visualize patient and treatment data, particularly in behavioral health and psychedelic-assisted therapy settings.

The company operates primarily in the United States with limited international exposure disclosed. EHAVE controls intellectual property related to its software platforms and has pursued growth through subsidiaries and acquired entities, including KetaDash (reported as a data analytics platform focused on ketamine-assisted therapy). The extent of active commercial deployments and recurring revenue remains data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, EHAVE positions itself as a data infrastructure provider for emerging behavioral health and psychedelic therapy markets. Its growth initiatives have emphasized platform development, regulatory-aligned data collection, and partnerships with clinics and research organizations rather than large-scale capital investments.

The company has reported acquisitions and internal investments intended to expand its analytics capabilities, including KetaDash, which is positioned as a core operating platform. EHAVE has indicated interest in emerging healthcare technologies and alternative treatment sectors; however, the commercial traction and financial impact of these initiatives cannot be fully verified from public filings and are data inconclusive based on available public sources.

Geographic Footprint

EHAVE is headquartered in the United States and primarily serves U.S.-based healthcare providers and organizations. Public disclosures do not indicate significant physical operations or revenue concentration outside North America.

While the company references broader market opportunities, there is limited verified information confirming material operational presence or investment activity across Europe, Asia-Pacific, or other international regions. Any global influence beyond the U.S. market remains data inconclusive based on available public sources.

Leadership & Governance

EHAVE is led by a small executive team typical of early-stage public companies, with leadership emphasizing innovation in digital health analytics and emerging therapeutic markets. Governance is overseen by a board of directors as disclosed in public filings, though detailed committee structures and independence metrics are limited in publicly available summaries.

Key executives disclosed in public materials include:

• Ben Kaplan – Chief Executive Officer
• Ben Kaplan – Chairman of the Board

Information regarding additional executive officers, founders beyond current leadership, or a broader management team is data inconclusive based on available public sources.